Download Files:

BMS CCR2 22

$120$2,000

Products Details

Product Description

– BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist with excellent binding affinity (binding IC50 of 5.1 nM) and potent functional antagonism (calcium flux IC50 of 18 nM and chemotaxis IC50 of 1 nM)[1][2].

Web ID

– HY-101908

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C28H34F3N5O4S

References

– [1]Cherney RJ, et al. Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists. J Med Chem. 2008 Feb 28;51(4):721-4.|[2]Kredel S, et al. High-content analysis of CCR2 antagonists on human primary monocytes. J Biomol Screen. 2011 Aug;16(7):683-93.|[3] D’Antoni ML, et al. Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression. J Leukoc Biol. 2018 Dec;104(6):1241-1252.

CAS Number

– 445479-97-0

Molecular Weight

– 593.66

Compound Purity

– 99.87

SMILES

– O=C(NCC(N[C@@H]1[C@H](NC(C2=CC=C(SC)C=C2)=O)CCCC1)=O)C3=CC(C(F)(F)F)=CC=C3NC(NC(C)C)=O

Clinical Information

– No Development Reported

Research Area

– Inflammation/Immunology; Endocrinology

Solubility

– DMSO : 250 mg/mL (ultrasonic)

Target

– CCR

Isoform

– CCR2

Pathway

– GPCR/G Protein;Immunology/Inflammation

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.